Vepdegestrant

Vepdegestrant (developmental code name GSK-4716) is an investigational drug that is being studied for the treatment of breast cancer and endometriosis. It is a selective estrogen receptor degrader (SERD) that is orally active.

History[edit | edit source]

Vepdegestrant was first developed by GlaxoSmithKline (GSK), a British multinational pharmaceutical company. The drug is currently in the clinical trial phase and is not yet approved for use by the Food and Drug Administration (FDA) or any other regulatory authority.

Mechanism of Action[edit | edit source]

As a SERD, Vepdegestrant works by binding to the estrogen receptor and inducing a conformational change that results in the degradation of the receptor. This prevents the receptor from being activated by estrogen, thereby inhibiting the growth of estrogen-dependent tumors.

Clinical Trials[edit | edit source]

Vepdegestrant has undergone several phases of clinical trials. In early trials, it demonstrated promising results in the treatment of breast cancer and endometriosis. However, further studies are needed to confirm these findings and to determine the optimal dosing regimen.

Potential Side Effects[edit | edit source]

As with any drug, Vepdegestrant may cause side effects. These can include nausea, vomiting, fatigue, and hot flashes. However, the severity and frequency of these side effects can vary among individuals.